This suggests that PI3K/Akt could be an alternative therapeutic target in CML, since ABCG2 seems to be regulated by PTEN through the PI3K/Akt pathway [117]. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.